The effects of olanzapine and risperidone on learning and retaining entry-level work skills

Clinical Schizophrenia and Related Psychoses

Volumn 3, Issue 3, 2009, Pages 133-141

  Kopelowicz, Alex ^a,d   Liberman, Robert Paul ^a   Wallace, Charles J ^a   Aguirre, Fabian ^b   Mintz, Jim ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c University of Texas Health Science Center   (United States)

^d San Fernando Mental Health Center   (United States)

Author keywords

Antipsychotic medications; Olanzapine; Risperidone; Schizophrenia; Skills training; Vocational rehabilitation; Work skills

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; JOB PERFORMANCE; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; OCCUPATIONAL THERAPY; OPEN STUDY; OUTPATIENT; PSYCHOTHERAPIST; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SKILL RETENTION; TASK PERFORMANCE; TRAINING; TREATMENT DURATION; VOCATIONAL REHABILITATION; WORK;

EID: 70449440462     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.3.3.2     Document Type: Article

References (32)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-564.
2. 2. Tandon R, Flelshhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79(2-3):145-155. (Pubitemid 41457255)
3. 3.WeidenP,AquilaR,StandardJ.Atypicalantipsychoticdrugsandlong- termoutcomeofschizophrenia.JClinPsychiatry1996;57(Suppl11):53-60. (Pubitemid26389786)
4. 4.HamiltonSH,EdgellET,RevicklDA,BreierA. Functionaloutcomesinschizophrenia: acomparisonofolanzapineandhaloperidolinaEuropeansample. IntClinPsychopharmacol2000;15(5):245-255.(Pubitemid30660959)
5. Aquila R, Weiden PJ, Emanuel M. Compliance and the rehabilitation alliance. J Clin Psychiatry 1999;60(Suppl. 19):23-27.
6. 6. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol In hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337(12):809 815. (Pubitemid 27391630)
7. Meyer PS, Bond GR, Tunis SL, McCoy ML. Comparison between the effects of atypical and traditional antipsychotics in work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry 2002;63(2):108-116.
8. 8.VelliganDI,PrihodaTJ,SulD,RitchJL,MaplesN,MillerAL. Theeffectivenessofquetiapineversusconventionalantipsychoticsinimprovingcogniti veandfunctionaloutcomesinstandardtreatmentsettings.JClinPsychiatry2003;64(5): 524-531.(Pubitemid36618280)
9. 9. Bond GR, Kim HW, Meyer PS, Gibson PJ, Tunis S, Evans JD, et al. Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics. Psychiatr Serv 2004;55(1):59-66. (Pubitemid 38045017)
10. 10. Jones PB, Barnes TR, Davles L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-1087. (Pubitemid 44498387)
11. Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al. Employment outcomes In a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res 2008;35(2):215-225.
12. 12. Percudani M, Barbui C, Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 2004;22(11):701-718. (Pubitemid 38998496)
13. First M, Spitzer R, Gibbon M, Williams J. Structured clinical interview for DSM-IV patient edition. Washington (DC): American Psychiatric Press; 1996.
14. 14. Kirkpatrick B, Buchanan RW, McKinney PD, Alphs LD, Carpenter WT. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30(2):119-123. (Pubitemid 20005923)
15. Kopelowicz A, Liberman RP, Wallace CJ, Aguirre F, Mintz J. Differential performance of job skills in schizophrenia: an experimental analysis. Journal of Rehabilitation 2006;72:31-39.
16. 16.LibermanRP,WallaceCJ,BlackwellG,KopelowiczA,VaccaroJV,MintzJ. Skillstrainingversusoccupationaltherapyforpersonswithpersistentschizophrenia. AmJPsychiatry1998;155(8):1087-1091.(Pubitemid28357735)
17. Stein F, Cutler S. Psychosocial occupational therapy: a holistic approach. San Diego (CA): Singular Press: 1998.
18. 18.ZarateR,LibermanRP,MintzJ,MasselHK. Validationofaworkcapacityevaluationinindividualswithpsychiatricdisorders. JournalofRehabilitation1998;4:28-34.(Pubitemid128165055)
19. 19. Kern RS, Liberman RP, Kopelowicz A, Mintz J, Green MF. Applications of errorless learning for improving work performance in schizophrenia. Am J Psychiatry 2002;159(11):1921-1926. (Pubitemid 35283260)
20. Ventura J, Green M, Shaner A, Liberman RP. Training and quality assurance on the BPRS: "the drift busters." International Journal of Methods in Psychiatric Research 1993;3:221-224.
21. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218-222.
22. 22.AddingtonD,AddlngtonJ,Maticka-TyndaleE. Assessingdepressioninschizophrenia:theCalgaryDepressionScale. BrJPsychiatrySuppl1993;(22):39-44.(Pubitemid23355888)
23. Chouinard G, Jones B, Remington G, Bloom C, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13(1):25-40.
24. SAS/STAT Software Version 9. Cary (North Carolina): SAS Institute: 2004.
25. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull 2000;26(1):21-46.
26. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res 2003;63(1-2):97-101.
27. 27. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002:159(6):1018-1028. (Pubitemid 34586949)
28. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role In the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004;65(3):361-372.
29. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetlapine and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8(3):457-472.
30. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-1087.
31. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al.; CATIE Investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164(3):428-436.
32. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetlapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am. J Psychiatry 2006:163(11):1918-1925.